Results of Annual General Meeting
Source: RNS
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Results of Annual General Meeting
Winsford, UK, 8 June 2021 - Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that at the Company's Annual General Meeting held today at 11 am at Guildhall Room, 85 Gresham Street, London, EC2V 7NQ, all resolutions were duly passed. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 30 April 2021.
The poll results were as follows.
|
Resolution
|
Title |
For (see note 2) |
Against (see note 2) |
||
|
No. of shares |
% |
No. of shares |
% |
||
|
1 |
Receive Annual Report and Accounts |
120,604,593 |
99.99 |
330,181 |
0.01 |
|
2 |
Approve the Remuneration Report |
120,394,128 |
99.73 |
5,741,835 |
0.27 |
|
3 |
Re-appoint Deloitte LLP as auditors |
114,997,737 |
95.24 |
12,404,976 |
4.76 |
|
4 |
Re-elect Peter Allen |
108,344,248 |
89.73 |
7,340,112 |
10.27 |
|
5 |
Re-elect Penny Freer |
108,168,473 |
93.65 |
107,035 |
6.35 |
|
6 |
Elect Grahame Cook |
120,642,189 |
99.91 |
596,840 |
0.09 |
|
7 |
Re-elect Chris Meredith |
120,152,803 |
99.51 |
335,974 |
0.49 |
|
8 |
Re-elect Eddie Johnson |
120,413,250 |
99.72 |
500 |
0.28 |
|
9 |
Declare final dividend |
120,757,509 |
99.99 |
411,061 |
0.01 |
|
10 |
Authorise allotment of shares |
115,674,585 |
99.65 |
12,886,611 |
0.35 |
|
11 |
Disapply pre-emption rights* |
107,809,178 |
89.32 |
897,163 |
10.68 |
|
12 |
Authorise purchase of own shares* |
94,716,196 |
99.06 |
330,181 |
0.94 |
* Special Resolution
|
Notes: 1. Votes "For" and "Against" are expressed as a percentage of votes received. 2. A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution. 3. Total number of shares in issue at close of business on 4 June = 215,650,692 shares. 56% of the voting capital was instructed. |
- Ends -
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer |
|
|
|
|
|
Consilium Strategic Communications |
Tel: +44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Matthew Neal / Matthew Cole |
AMS@consilium-comms.com |
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: +44 (0) 20 7597 5970 |
|
Daniel Adams / Gary Clarence / Patrick Robb |
|
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a leading coater and converter of materials predominately for woundcare and bio-diagnostics products based in the UK.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has approximately 700 employees. For more information, please see www.admedsol.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
